Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Post PCI FFR

Much research has been done on the usefulness of functional testing such as fractional Flow reserve (FFR) after percutaneous coronary intervention (PCI), resulting in the correlation of pathological FFR values with major adverse events at 6 months, as shown by Pijls, et al.

The impact of post PCI FFR on prognosis has not been studied in contemporary cohorts, with the latest generation stents and in complex scenarios, such as multivessel disease, that can be treated both with PCI and coronary artery bypass graft (CABG). 

The FAME 3 study compared FFR guided multivessel PCI against CABG (excluding left main patients). This study did not reach non-inferiority for the composite of death, MI, stroke, or repeat revascularization. Despite these results, a subanalysis was conducted to assess the prognostic value of post PCI FFR in these patients.

Primary end point was target vessel failure (TVF) defined as the composite of cardiac death, target vessel MI and repeat revascularization at one year. 

Read also: Trans-Stent Gradient as a Predictor of Adverse Events at Followup.

Of the 1,500 FAME 3 patients, 757 were randomized to the FFR branch, and 61% of these pateints received post PCI FFR. As per protocol, there were no changes in therapy after the new measurement. 48% of measurements were from the anterior descending, 24.2% the circumflex and 27.6% the right coronary. Mean FFR value was 0.89 (RIC 0.85), and 9.1% of FFR cases was lower than 0.80. 

Multiple regression analysis showed predictors of post PCI FFR were male sex, anterior descending localization, minimal stent diameter and total stent length. Pathological post PCI FFR value were a predictor of target vessel failure (TVF) (HR=0.67, CI 95% 0.48-0.93, for 0.1 unit increase, p=0.165). A ROC curve analysis was done, which determined 0.88 as the best cutoff value to define TVF events.

Upon multivariable analysis, the independent factors of primary end point were kidney disease (HR 5.71, CI 95% 1.91-17.1, P=0.002) and continuously altered FFR values (HR 0.67, CI 0.49-0.91; P=0.03).

Read also: Severe Mitral Regurgitation and Cardiogenic Shock: Is Edge-to-Edge a Valid Strategy?

There was another analysis of patients receiving intravascular imaging (11.1% in the FFR branch FFR), which showed no higher rates of cardiac mortality, MI or repeat revascularization compared against patients not getting IVUS/OCT (log-rank P=0.21).

Conclusions

This FAME 3 subanalysis showed altered FFR values after PCI in patients with multivessel disease were a predictor of cardiovascular events, mainly due to target vessel failure at one year, while the use of intravascular imaging did not reduce the studied outcomes.  

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Prognostic Value of Measuring Fractional Flow Reserve After Percutaneous Coronary Intervention in Patients With Complex Coronary Artery Disease: Insights From the FAME 3 Trial.

Reference: Piroth, Zsolt et al. “Prognostic Value of Measuring Fractional Flow Reserve After Percutaneous Coronary Intervention in Patients With Complex Coronary Artery Disease: Insights From the FAME 3 Trial.” Circulation. Cardiovascular interventions vol. 15,11 (2022): 884-891. doi:10.1161/CIRCINTERVENTIONS.122.012542.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...